ANN ARBOR, MI (February 4, 2019) — Genomenon®, the leading genomic search company, announced today that industry veteran David Anstey has joined the executive team as the company’s Vice President of Sales. Anstey was most recently the Vice President of Sales at Fabric Genomics, which provides bioinformatics solutions to clinical labs.
In his new role at Genomenon, Anstey is responsible for building out and leading the company’s sales and business development efforts. Prior to his position at Fabric Genomics, Anstey held positions at Illumina, YarcData, and IDBS, selling informatics solutions to genomics labs and pharmaceutical companies. His background and experience align well with Genomenon’s focus on those markets.
“What I found most compelling about Genomenon is its leadership position in genomic search for clinical decision support and its role in advancing pharmaceutical research and development” said Anstey. “Much of the genomic data that is critical to precision medicine has been buried deep inside millions of scientific publications. Genomenon unlocks this data and provides a comprehensive genomic landscape that accelerates patient diagnosis and drug discovery.”
Last month, Genomenon announced a $2.5 million equity financing round to fund the acceleration of its commercial efforts. Anstey is actively recruiting sales talent to drive that acceleration.
“Dave brings 20 years of experience selling into life science companies, and he has an excellent track record of driving growth and building partnerships with his customers” said Mike Klein, CEO of Genomenon. “We’re excited to have Dave join our team and help drive our success.”
Genomenon puts genomic research at doctor’s fingertips for faster; more comprehensive diagnosis and treatment decisions. Our flagship product, the Mastermind Genomic Search Engine provides immediate insight into the published genomic research for every disease, gene, and variant found in the literature.
Used by hundreds of diagnostic labs around the world, Mastermind accelerates genomic interpretation by providing unique insight into genomic relationships found in the full text of millions of scientific articles.
Pharmaceutical researchers license the Mastermind database for a comprehensive genomic landscape associated with any given disease – to identify and prioritize genomic biomarkers for drug discovery and clinical trial targets. For more information, visit genomenon.com.